Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset.
Tymms K, Butcher BE, Sletten TL, Smith T, O'Sullivan C, Littlejohn G, Sadler R, Tronnberg R, Griffiths H; OPAL consortium. Tymms K, et al. Among authors: tronnberg r. Clin Rheumatol. 2022 Apr;41(4):1105-1114. doi: 10.1007/s10067-021-05953-8. Epub 2021 Nov 26. Clin Rheumatol. 2022. PMID: 34825268 Free PMC article.
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P, Manuelpillai N, Dolianitis C, Cains GD, Mate E, Tronnberg R, Baker C. Foley P, et al. Among authors: tronnberg r. Australas J Dermatol. 2022 Aug;63(3):303-311. doi: 10.1111/ajd.13895. Epub 2022 Jul 9. Australas J Dermatol. 2022. PMID: 35809080 Free PMC article.
Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
Sen HN, Drye LT, Goldstein DA, Larson TA, Merrill PT, Pavan PR, Sheppard JD, Burke A, Srivastava SK, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Sen HN, et al. Ocul Immunol Inflamm. 2012 Apr;20(2):104-12. doi: 10.3109/09273948.2011.647228. Ocul Immunol Inflamm. 2012. PMID: 22409563 Free PMC article. Clinical Trial.
Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5. Ophthalmology. 2014. PMID: 24908205 Free PMC article. Clinical Trial.
The Early Preclinical Development Program for Locally Administered Investigational Medicinal Products in Ophthalmology: Preclinical Data Required for Starting a First-in-Human Clinical Trial in Europe-Basic Considerations and 2 Case Studies.
Toggenburger A, Trönnberg R, Galland A, Mathis GA. Toggenburger A, et al. Among authors: tronnberg r. Ther Innov Regul Sci. 2018 May;52(3):321-328. doi: 10.1177/2168479017725110. Epub 2017 Sep 5. Ther Innov Regul Sci. 2018. PMID: 29714531
Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Kempen JH, et al. Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18. Am J Ophthalmol. 2015. PMID: 26386159 Free PMC article. Clinical Trial.
13 results